The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties.

Vasc Health Risk Manag · 2025 · PMC12333640 · PMID 40786695

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Over a 2-year follow-up, rituximab and IL-6 inhibitors were associated with numerically higher MACE incidence (196 and 111 per 10,000 person-years, respectively), though these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.